Table 2. Concordance across platforms.
| N positive concordance/N | IHC+(%) | FISH amplified (%) | Mutation (%) | |
|---|---|---|---|---|
| cKIT | 0/23 | 65/1441 (4.5) | NA | 12/749 (1.6) All VUS* |
| cMET | 1/751 (IHC/ISH) 0/442 (ISH/NGS) 1/567 (IHC/NGS) |
43/970 (4.4) | 20/761 (2.6) | 15/588 (2.6) All VUS* |
| EGFR | 2/45 (IHC/ISH) 0/16 (ISH/NGS) 0/11 (IHC/NGS) |
80/217 (36.9) | 181/1072 (16.9) | 0/608 (0) |
| HER2 | 0/910 (IHC/ISH) 0/518 (ISH/NGS) 0/555 (IHC/NGS |
1/2409 (0.04) *Case with HER2 overexpression was not tested on other platforms |
9/925 (1.0) | 0/573 (0) |
| PDGFR | NA | 135/610 (22.1) | NA | 1/581 (0) |
| PTEN | 8/539 (IHC/NGS) | Loss 910/2358 (38.6) | NA | 16/557(15 cases) (3.2) *8/15 cases with PTEN mutation had PTEN loss *7/15 cases with mutation were VUS without PTEN loss |
| TOPO2A | 0/36(IHC/FISH) | 1117/2114 (52.8) | 2/118 (1.7) | NA |
*
VUS = variant of unknown significance